Lito and colleagues recently demonstrated that MEK activated by CRAF in melanoma and lung cancer cells is less sensitive to MEK inhibitors than when activated by BRAF V600E [49], which is confirmed by the response of KTC1-VEM2 cells to combination treatment with vemurafenib and the MEK inhibitor AZD6244. Here, MAP2K7 is linked to lung cancer.